tbuckley/cabot-search huggingface dataset:
New drugs for peptic ulcer.
Authors: Greco Fa, Richardson Rl, Stroup Sl, Oldham Small
Journal: BMJ (1980)

untreated patients.5In untreated patients with "extensive" disease the median survival is one month; with drug treatment this can be pushed up to almost one year.'Staging is, therefore, of more than academic interest in lung cancer, and a simple sequential programme has been evolved using mostly non-invasive techniques of isotope scanning and computed tomography.Restaging is now becoming as important as initial staging in small-cell cancer, so that complete remission can be defined; the same pattern of tests is used, together with fibreoptic bronchoscopy, for accurate reassessment of the primary tumour. 1
Vacation Lectures on Fibrinous Deposition in the Heart: Its History and Practical Meaning
Authors: B. W. Richardson
Journal: BMJ (1860)

health so much impaired, that at one time I was on the very point of proposing excision, you will tee that the child is now stout and well, that the limb is a very useful one, and the knee is only partially stiff.The relations have brought these children here to-day for inspection; for it is now many months since some of them were discharged from the Hospital, and,
Virtual reality technologies soon to be introduced into surgery
Journal: BMJ (2001)

Thyroxine does not benefit euthyroid people with symptoms of hypothyroidism Thyroxine is no more effective than placebo in improving cognitive function and psychological wellbeing in patients with symptoms of hypothyroidism but with thyroid function tests within the normal range.In addition, thyroxine does not improve cognitive function and psychological wellbeing in healthy adults.Pollock and colleagues (p 891) conducted a randomised, double blind, placebo crossover trial on 22 patients with symptoms of hypothyroidism, but biochemically euthyroid, and 19 healthy controls.They also found that there was no significant changes in clinical measurements such as blood pressure, pulse rate, or weight during the study. Metered dose inhalers are most cost effective for asthma drugsPressurised metered dose inhalers are the most cost effective method for delivering 2 agonists and corticosteroids in patients with stable asthma.In two systematic reviews (pp 896 and 901), the National Health Technology Assessment Inhaler Review Group found no significant differences between pressurised metered dose inhalers and other inhaler devices.These included dry powder inhalers, breath actuated devices, and hydrofluoroalkane devices.Use of a spacer device did not affect the results.Since pressurised metered dose inhalers are usually the cheapest form of treatment, they should be used as first line treatment unless there are specific contraindications.
Government Services
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Malignant hyperpyrexia during anesthesia
Authors: J. F. Arens
Journal: JAMA (1971)

Malignant hyperpyrexia is a rare complication following anesthesia but one that is fatal in more than 70% of cases. In one case studied the patient's temperature reached 104 F (40.0 C). With vigorous treatment she survived in spite of other life-threatening complications. In the syndrome of fulminant hyperpyrexia, prevention is the prime consideration. If a patient develops muscular rigidity, exceedingly hard muscular fasciculations, or trismus following intravenous administration of succinylcholine, the operative procedure should be postponed unless it is an emergency. Temperature recording should be routinely used on all patients undergoing general anesthesia. If possible, spinal or other forms of conduction anesthesia should be employed in a patient who has shown a paradoxical response to succinylcholine intravenously. If block anesthesia cannot be used, then use of nitrous oxide, oxygen, and curare seems to be a rational technique.
BRIGHT'S DISEASE—UREA—SEROUS MEMBRANES.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I study of Gliadel&lt;SUP&gt;™&lt;/SUP&gt; wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas
Authors: Sridharan Gururangan, Ilkcan Cokgor, Jeremy N. Rich, Shari Edwards, Mary Lou Affronti, Jennifer A. Quinn, James E. Herndon, James M. Provenzale, Roger E. McLendon, Sandra Tourt-Uhlig, John H. Sampson, Valerie Stafford-Fox, Sara Zaknoen, Maureen Early, Alan H. Friedman, Henry S. Friedman
Journal: Neuro-Oncology (2001)

Both Gliadel™ wafers [1,3-bis(2-chloroethyl)-1-nitrosourea] and temozolomide (TEMO) have been shown in independent studies to prolong survival of patients with recurrent malignant glioma following surgery and radiotherapy. On the basis of preclinical evidence of synergism between Gliadel wafers and TEMO, a phase I study was designed to evaluate the toxicity of combining these 2 agents in the treatment of patients with recurrent supratentorial malignant glioma. All patients had surgical resection of the tumor at relapse, and up to 8 Gliadel (3.85%) wafers were placed in the surgical cavity following resection. Two weeks after surgery, TEMO was given orally daily for 5 days. Cohorts of 3 patients received TEMO at daily doses of 100 mg/m2, 150 mg/m2, and 200 mg/m2, respectively. Patients were assessed for toxicity 4 weeks after start of the first course of TEMO. Contrast-enhanced MRI of the brain was used to assess tumor response after the first cycle of TEMO. Patients with stable disease or response after the first cycle of TEMO were allowed to continue treatment at the same dose every 4 weeks for 12 cycles or until disease progression or unacceptable toxicity. Ten patients with a median age of 47 years (range, 22-66 years) were enrolled in this study. There were 7 patients with glioblastoma multiforme and 3 patients with anaplastic astrocytoma. Three patients were treated with TEMO at the first dose level of 100 mg/m2, 4 at the second dose level of 150 mg/m2, and 3 at the third dose level of 200 mg/m2. The 10 patients received a median of 3 cycles (range, 1-12 cycles) of TEMO following placement of Gliadel wafers. The treatment was well tolerated, with only 1 patient suffering grade III thrombocytopenia at the highest dose level. Two patients at each dose level had no evidence of disease progression after treatment. Four patients suffered progressive disease on therapy. Our study demonstrates that TEMO can be given safely after placement of Gliadel (3.85%) wafers. The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days.
Recommendations for the registration of drugs used in the treatment of osteoarthritis. Group for the respect of ethics and excellence in science (GREES): osteoarthritis section.
Journal: Annals of the Rheumatic Diseases (1996)

Recommendations for the registration of drugs used in the treatment of osteoarthritis Group for the Respect of Ethics and Excellence in Science (GREES)*: osteoarthritis section Osteoarthritis is a disorder which can potentially affect all joints.It is characterised by degeneration and regeneration of articular cartilage and bone.The pathological changes can be focal or more generalised and these changes correlate poorly with clinical symptoms and signs.However, there is some evi- dence that asymptomatic osteoarthritis, diagnosed radiologically, is a precursor of symptomatic disease.Osteoarthritis, particularly of the large joints of the lower limbs-for example, knees and hips-is now widely recognised as a major cause of chronic disability in the elderly population.Recent technical advances have allowed symptomatic and structural changes associated with osteoarthritis to be measured with greater precision than previously.These advances, together with increased knowledge of the bio- chemical mechanisms involved in the osteoarthritic disease process, have encouraged clinical evaluation of several agents which may have a beneficial effect on the disease process.Currently, there are inconsistencies in the classification of drugs for the treatment of osteoarthritis and the indications for their use.These inconsistencies are reflected in different approaches of national licensing authorities to the registration of drugs for the treatment of osteoarthritis.Accordingly, there seems to be an urgent need to standardise the registration requirements of such drugs.This prompted the formation of a European Working Group to consider the issue.The group comprised clinical and basic scientists working in the field of osteoarthritis in academia and the pharmaceutical industry and representatives of national drug licensing authorities.This report classifies drugs for the treatment of osteo- arthritis as symptom modifying, structure modifying, or both and gives recommendations for the preclinical and clinical studies con- sidered to be necessary prerequisites at this time for the registration of such drugs.The recommendations are based on currently available knowledge and technology.They will need updating as further scientific progress is made in this field.
Concerning the Need for More Sophisticated Animal Models in Sensory Behavioral Toxicology
Authors: William C. Stebbins
Journal: Environmental Health Perspectives (1982)

It is necessary but not sufficient to develop laboratory animal models in sensory behavioral toxicology for screening toxic substances and for the analysis of sensory impairment at threshold levels of stimulation. It is important to develop more thorough and quantitative tests of impairment which in their greater complexity more accurately reflect the conditions and environmental demands of day-to-day life. Such greater complexity in stimulus conditions and behavior may also aid in monitoring not merely the state of the receptor organ but more central nervous processes which are the focus of assault by many known toxic substances. Techniques are described for studying such acoustic behaviors as intensity discrimination and frequency selectivity in guinea pig and monkey by use of operant conditioning procedures coupled with sensory testing (psychophysical) methods. Impaired auditory selectively and discrimination is shown to be correlated with histopathological changes in the inner ear. Slight modification of these procedures in animals may be used to investigate acoustically more intricate behaviors such as sound localization and the perception of frequency modulated acoustic signals as elements of speech and communication sounds.
Reference Committees 1984 Interim Meeting
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OSTEOPATHY IN NEW YORK.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The risk of myocardial infarction associated with antihypertensive drug therapies
Authors: B. M. Psaty
Journal: JAMA (1995)

<h3>Objective.</h3> —To assess the association between first myocardial infarction and the use of antihypertensive agents. <h3>Design and Setting.</h3> —We conducted a population-based case-control study among enrollees of the Group Health Cooperative of Puget Sound (GHC). <h3>Patients and Methods.</h3> —Cases were hypertensive patients who sustained a first fatal or nonfatal myocardial infarction from 1986 through 1993 among women and from 1989 through 1993 among men. Controls were a stratified random sample of hypertensive GHC enrollees, frequency matched to the cases on age, sex, and calendar year. All 623 cases and 2032 controls had pharmacologically treated hypertension. Data collection included a review of the ambulatory medical record and a brief telephone interview of consenting survivors. Antihypertensive therapy was assessed using the GHC's computerized pharmacy database. <h3>Results.</h3> —The first analysis included only the 335 cases and 1395 controls initially free of cardiovascular disease. Compared with users of diuretics alone, the adjusted risk ratio of myocardial infarction was increased by about 60% among users of calcium channel blockers with or without diuretics (risk ratio=1.62; 95% confidence interval [CI], 1.11 to 2.34;<i>P</i>=.01). The second analysis was restricted to 384 cases and 1108 controls who were taking either a calcium channel blocker or a β-blocker. Among these subjects, the use of calcium channel blockers compared with β-blockers was associated with about a 60% increase in the adjusted risk of myocardial infarction (risk ratio=1.57; 95% CI, 1.21 to 2.04;<i>P</i>&lt;.001). While high doses of β-blockers were associated with a decreased risk of myocardial infarction (trend<i>P</i>=.04), high doses of calcium channel blockers were associated with an increased risk (trend<i>P</i>&lt;.01). <h3>Conclusions.</h3> —In this study of hypertensive patients, the use of short-acting calcium channel blockers, especially in high doses, was associated with an increased risk of myocardial infarction. Ongoing large-scale clinical trials will assess the effect of various antihypertensive therapies, including calcium channel blockers, on several important cardiovascular end points. Until these results are available, the findings of this study support the current guidelines from the Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure that recommend diuretics and β-blockers as first-line agents unless contraindicated, unacceptable, or not tolerated. (<i>JAMA</i>. 1995;274:620-625)
Transition Metal-Binding Proteins from Three Chesapeake Bay Fish Species
Authors: Rolf Andersen, John Frazier, P. C. Huang
Journal: Environmental Health Perspectives (1986)

Three species of Chesapeake Bay fish were collected, and endogenous levels of metal binding protein (MBP) were determined.In addition, the induction of metal-binding proteins by cadmium was studied.Livers from freshly caught fish were extracted and chromatographed on Sephadex G-75 to resolve MBP in the 5 to 20 kdalton range.All species studied exhibit measurable but varied levels of endogenous MBPs in the molecular weight range investigated, mostly as a copper protein complex.Upon induction with cadmium, the total MBP content increased in both catfish (Ictalurus punctatus) and striped bass (Morone saxatilis), with significant amounts of cadmium bound to the protein.In white perch (Morone americana), induction of MBPs with cadmium could not be demonstrated due to the large amount of constitutive Cu-BP present, although significant quantities of cadmium were bound to MBP.Electrophoresis in polyacrylamide gel was used to further identify these MBPs.Electrochemical analysis of the MBPs by polarography indicated that the wave properties of the fish MBPs resemble that of rat metallothionein.In conclusion, these studies indicate that: MBPs are present in estuarine fish from the Chesapeake Bay; concentrations of MBPs and their inducibility by exogenous cadmium vary with species, and fish MBPs may be related to mammalian metallothionein.
<i>Traitement de la Syphilis.</i>—Par Alfred Fournier. Professeur à la Faculté de Médecine, Membre de l' Académie de Médecine, Mèdecin de l'Hôpital Saint Louis. Paris: Rueff et Cie. [The Treatment of Syphilis, by Alfred Fournier]
Journal: American Journal of Psychiatry (1893)
Questions and Answers
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CURRENT LITERATURE
Journal: British Journal of Dermatology (1921)

British Journal of DermatologyVolume 33, Issue 7 p. 274-279 CURRENT LITERATURE First published: July 1921 https://doi.org/10.1111/j.1365-2133.1921.tb09049.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Volume33, Issue7July 1921Pages 274-279 RelatedInformation
Tissue Plasminogen Activator: The Biochemistry And Pharmacology Of Variants Produced By Mutagenesis
Authors: D. Higgins
Journal: The Annual Review of Pharmacology and Toxicology (1990)

Since the spread of tobacco from the Americas hundreds of years ago, tobacco cigarettes and, more recently, alternative tobacco products have become global products of nicotine addiction. Within the evolving alternative tobacco product space, electronic ...Read More
Aspirin Hazard
Authors: R. H. Bodenbender
Journal: JAMA (1971)

<h3>To the Editor.—</h3> After reading Quick's letters (<b>213</b>:1689, 1970;<b>214</b>:1565, 1970) alerting the medical profession about the potential hazard of aspirin in the hemophiliac, I am motivated to add my clinical impression of a recent case. An 11-year-old boy with no previous bleeding episodes, but with a suggestive family history for hemophilia, was treated because of persistent bleeding one week after a tooth extraction. On admission his hemoglobin level was 5.7 gm/100 ml and his hematocrit reading was 17%. Laboratory work-up revealed a prolonged prothrombin consumption time and prolonged thromboplastin generation test. He received cryoprecipitate and the bleeding stopped. He was subsequently seen at a large midwest medical center and found to have 15% of normal factor VIII. Further history indicated that he had had a toothache approximately one week prior to this extraction during which time he received salicylates for pain. The onset of this hemophiliac's first